Introduction
============

As the second leading cancer type for the estimated new cancer cases, lung cancer represents the major cause of cancer death in both females and males.[@b1-ott-8-2731] Despite research on the diagnosis of lung cancer and the use of increasingly advanced technology in its treatment, the prognosis of lung cancer is still poor. Thus, there is an urgent need for development of prognostic serum biomarkers for the prognosis of lung cancer, which would help clinicians to adopt preventive and personalized medicine for patients with lung cancer.

In recent years, accumulating evidence shown that increased systemic inflammation is associated with poor overall survival (OS) in numerous cancers.[@b2-ott-8-2731]--[@b5-ott-8-2731] Inflammation is a crucial component of tumor microenvironment.[@b5-ott-8-2731] Inflammatory cells in the tumor microenvironment have important effects on tumor development, and markers of systemic inflammation may provide significant information for prognostication.[@b6-ott-8-2731],[@b7-ott-8-2731] Neutrophil to lymphocyte ratio (NLR), calculated as a simple ratio between neutrophil and lymphocyte counts, an index of systemic inflammation, has been related to poor survival for a variety of malignant tumors.[@b8-ott-8-2731]--[@b12-ott-8-2731]

Several meta-analyses have showed that NLR has been linked to tumor progression and clinical outcome in many cancers besides lung cancer.[@b13-ott-8-2731]--[@b15-ott-8-2731] Nevertheless, conflicting results have emerged regarding the use of NLR to predict disease progression-free survival (PFS) and OS in lung cancer.[@b16-ott-8-2731],[@b17-ott-8-2731] Therefore, it is necessary to perform a systemic review and meta-analysis to comprehensively and systematically evaluate the prognostic value of NLR in lung cancer. This study sought to assess and explore the prognostics of NLR for OS and PFS in patients with lung cancer by pooling outcomes from the available data.

Methods
=======

Search strategy
---------------

We performed a comprehensive literature search of articles through the following databases without date limitation: PubMed, Ovid, the Cochrane Library, and Web of Science databases. The search was updated to May 2015. The main search terms included (NLR or neutrophil to lymphocyte ratio or neutrophil lymphocyte ratio or neutrophil-to-lymphocyte ratio) and (lung cancer or lung carcinoma or NSCLC or SCLC). A manual search of reference lists and potential related articles was also performed.

Data extraction
---------------

All candidate studies were evaluated and extracted by two independent investigators (Qing-Tao Zhao and Yong Yang). The articles, which could not excluded based on title and abstract, were retrieved for full-text review. If disagreement occurred, two investigators discussed and arrived at consensus with the third investigator (Shun Xu).

Inclusion criteria
------------------

Studies were included in this meta-analysis if they met the following criteria: 1) Patients with lung cancer in the studies were confirmed by pathological examination, 2) all evaluation indicators were derived from NLR in serum, 3) correlation of NLR with OS and/or PFS of patients with lung cancer was reported, and 4) articles that were not directly recording hazard ratios (HRs) and 95% confidence interval (CI) were allowed if we could rebuild them by *P*-values and other data reported.[@b18-ott-8-2731]

Exclusion criteria
------------------

We excluded articles with any of the following characteristics: 1) abstracts, letters, reviews, expert opinions, case reports, or nonclinical studies; 2) no access to the studies with sufficient data for estimating HR and 95% CI; 3) studies had duplicate or overlapping data; and 4) studies were not written in English.

Data extraction and quality assessment
--------------------------------------

The following items were recorded: first author's name, year of publication, country, total number of cases and sex, follow-ups, stage, cut-off value, cancer type, and HRs with 95% CIs. The Newcastle--Ottawa Scale (NOS) was used to assess each of the included studies' quality by two independent investigators (Qing-Tao Zhao and Yong Yang).[@b19-ott-8-2731] The NOS consists of three parts: selection (four points), comparability (two points), and outcome assessment (three points). Studies labeled with six or more points were considered to be of high quality.

Statistical analysis
--------------------

HR and 95% CI were procured or estimated from each study according to the methods by Parmar et al.[@b18-ott-8-2731] A HR \>1 indicated a worse prognosis in patients with lung cancer with high expression of NLR. For each meta-analysis, the Cochrane's *Q* statistic was undertaken to assess the heterogeneity of the included trials. *I*^2^ \<50% represented acceptable no remarkable interstudy heterogeneity, and the fixed-effects (Mantel--Haenszel method) model was applied. Otherwise, the random-effects (DerSimonian--Laird method) model was used. Subgroup analysis and meta-regression analyses were conducted to explore and explain the diversity (heterogeneity) among the results of different studies. All *P*-values were two-sided, and *P*\<0.05 was considered statistically significant. Publication bias was assessed by Begg's rank correlation test and Egger's regression asymmetry test.[@b20-ott-8-2731] Trim and fill method was used to assess potential asymmetry in the funnel plot.[@b21-ott-8-2731] Statistical analyses were performed using STATA statistical software version 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Study characteristics
---------------------

The flow chart of the study selection for the meta-analysis is shown in [Figure 1](#f1-ott-8-2731){ref-type="fig"}. Twenty-two studies with a total of 7,054 patients[@b16-ott-8-2731],[@b17-ott-8-2731],[@b22-ott-8-2731]--[@b41-ott-8-2731] were retrieved according to the inclusion and exclusion criteria after careful reading and selection. Of 22 articles, 21 articles investigated the prognostic role of NLR for OS and nine for PFS. Nine studies were from Western countries, including three studies from the US, two studies from the UK, one study from Italy, Spain, Belgium, and Canada. Thirteen studies were from Eastern countries, including five from People's Republic of China, four from Turkey, three from Korea, and one from Japan. All of the studies were retrospective cohort studies. All were reported within the past 5 years, and 82% were reported in 2013--2015. The characteristics of the included studies were summarized in [Table 1](#t1-ott-8-2731){ref-type="table"}.

NLR and OS in lung cancer
-------------------------

Twenty-one studies evaluated OS for NLR. Though with significant heterogeneity (*I*^2^ =81.8%, *P*\<0.001), therefore, a random-effects model was applied. The pooled HR of 1.51 (95% CI, 1.33--1.71; *P*\<0.001; [Figure 2](#f2-ott-8-2731){ref-type="fig"}) showed that patients with elevated NLR were expected to have shorter OS after the treatment.

NLR and PFS in lung cancer
--------------------------

Nine studies evaluated PFS for NLR. Meta-analysis using the random-effects model demonstrated that high NLR was significantly associated with shorter PFS (HR, 1.33; 95% CI, 1.07--1.67; *P*=0.012; [Figure 3](#f3-ott-8-2731){ref-type="fig"}) with heterogeneity (*I*^2^ =80.5%, *P*\<0.001).

Subgroup analyses
-----------------

We further explored potential causes of the heterogeneity in the meta-analysis. Regarding OS, subgroup analysis was performed by the study therapeutic (surgical and chemotherapy), region (eastern and western), NLR cut-off value (5 and \<5), type (non-small-cell lung cancer \[NSCLC\], small-cell lung cancer \[SCLC\], and NSCLC/SCLC), stage (advanced: III/IV and stage I to stage IV: I/II/III/IV). Regarding PFS, subgroup analyses were also performed based on the treatment; NLR cut-off value and region are shown in [Table 2](#t2-ott-8-2731){ref-type="table"}. The pooled results were similar to those for OS. Majority of the subgroup analysis did not alter the prognostic role of NLR in OS/PFS substantially ([Table 2](#t2-ott-8-2731){ref-type="table"}).

Publication bias
----------------

Begg's funnel plot and Egger's test linear regression test were presented for the visual assessment of overt publication bias for the included cohorts in NLR. OS and PFS/disease-free survival (DFS) publication bias was not obvious, publication bias was detected for OS (*Pr*\>\|*z*\| =0.928 for Begg's test and *P*\>\|*t*\| =0.981 for Egger's test) and PFS/DFS (*Pr*\>\|*z*\| =0.64 for Begg's test and *P*\>\|*t*\| =0.994 for Egger's test).

Discussion
==========

Inflammation plays an important role in tumor initiation and progression.[@b4-ott-8-2731],[@b42-ott-8-2731] The exact mechanism between inflammation and tumor in these patients with cancer was still undefined. Inflammation-related enhanced neutrophil response and/or suppression of lymphocyte leading to a high NLR participates in communication between the microenvironment and tumor cells.[@b6-ott-8-2731],[@b7-ott-8-2731],[@b43-ott-8-2731] The high NLR potentially balances the functions of neutrophils and lymphocyte, making it a valuable prognostic role in gastric, hepatocellular, colorectal cancers, and so on.[@b9-ott-8-2731],[@b10-ott-8-2731],[@b12-ott-8-2731],[@b44-ott-8-2731] The mechanisms underlying the complex interplay between high NLR and poor outcome of numerous patients with cancers are poorly understood.[@b8-ott-8-2731],[@b44-ott-8-2731] One reason of the prognostic impact of NLR may be an association of elevated levels of NLR with inflammation. Neutrophil restrain the immune system by suppressing the cytolytic activity of activated T-cells, lymphocytes, and natural killer cells.[@b2-ott-8-2731],[@b45-ott-8-2731] However, the significance of lymphocytes has been highlighted in some studies in which increasing infiltration of tumors with lymphocytes may play a key role in cytotoxic treatment and prognosis in patients with cancer.[@b4-ott-8-2731],[@b46-ott-8-2731]

NLR was frequently used as an inflammatory marker, while its prognostic role in lung cancer was revealed just during the recent years. The present meta-analysis demonstrated that the elevated level of NLR is associated with the poor survival of lung cancer. A prognostic role was demonstrated for both OS and PFS of patients with lung cancer.[@b47-ott-8-2731] Similar to our study, two recent meta-analyses confirmed the prognostic value of the NLR in colorectal cancer and hepatocellular carcinoma.[@b13-ott-8-2731],[@b14-ott-8-2731] Though with heterogeneity, subgroup estimation in the present study showed that high NLR was an effective prognostic factor for poor OS of patients with lung cancer who received various types of treatment including surgical resection and chemotherapy. There was also a significant association between NLR and therapeutic and cut-off value NLR =5/\<5. Taking all these into consideration, NLR is a promising prognostic inflammation marker helpful for the clinical decision-making process regarding lung cancer treatment and outcomes.

Limitations of this meta-analysis deserve comment. First, the majority of the enrolled studies were retrospective, which was more susceptible to some biases. Second, heterogeneity is a potential problem that may affect the interpretation of the results of all meta-analyses. The presence of heterogeneity may result from many other factors, including age distribution, sex, NLR cut-off value, and so on. Third, NLR was not included in the multivariate analysis because it failed to gain statistical significance in the univariate analysis. The corresponding HR and 95% CI could only be retrieved from univariate analysis. The accuracy of the pooled estimates may thus be impaired. Fourth, publication bias inevitably hides in meta-analysis since positive results were more likely to be published than negative ones. A tendency for journals to only publish positive results leads to a larger magnitude of an association in pooled analysis than the actual value.

In conclusion, this meta-analysis demonstrated that the high NLR is associated with worse prognosis for patients with lung cancer. NLR seems to be a convenient, repeated, inexpensive, widely available, and reliable to predict the survival and treatment response of patients with lung cancer. In future, more research with better design to test this hypothesis is necessary.
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![Flow chart of the included studies.\
**Abbreviations:** HR, hazard ratio; CI, confidence interval; NLR, neutrophil to lymphocyte ratio; ESR, erythrocyte sedimentation rate.](ott-8-2731Fig1){#f1-ott-8-2731}

![Meta-analysis of the association between NLR and OS of lung cancer. Results are presented as individual and pooled hazard ratio (HR), and 95% confidence interval (CI).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** NLR, neutrophil to lymphocyte ratio; OS, overall survival.](ott-8-2731Fig2){#f2-ott-8-2731}

![Meta-analysis of the association between NLR and PFS of lung cancer. Results are presented as individual and pooled hazard ratio (HR), and 95% confidence interval (CI).\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** NLR, neutrophil to lymphocyte ratio; PFS, progression-free survival.](ott-8-2731Fig3){#f3-ott-8-2731}

###### 

Main characteristics of all the studies included in the meta-analysis

  Study cohort                       Year   Study region                 No (M/F)          Follow-up (months) (median and range)   Treatment                   Age (years) (median and range)           Cut-off   Outcome   Stage         Type         HR       NOS score
  ---------------------------------- ------ ---------------------------- ----------------- --------------------------------------- --------------------------- ---------------------------------------- --------- --------- ------------- ------------ -------- -----------
  Cannon et al[@b22-ott-8-2731]      2015   USA                          59 (31/28)        17                                      Radiation                   70 (48--89)                              2.98      OS        I             NSCLC        E(U)     7
  Choi et al[@b23-ott-8-2731]        2015   USA                          1,139 (602/537)   102                                     Surgery                     64.73                                    5         RFS/OS    I/II/III      NSCLC        R(U/M)   7
  Kos et al[@b24-ott-8-2731]         2015   Turkey                       138 (124/14)      NR                                      NR                          57 (26--83)                              3.24      OS        I/II/III/IV   NSCLC        R(U/M)   6
  Mitchell et al[@b25-ott-8-2731]    2015   Canada                       1,157 (797/360)   58.7                                    Chemotherapy radiotherapy   61 (19--89)                              5         OS        I/II/III/IV   NSCLC        R(U)     6
  Zhang et al[@b26-ott-8-2731]       2015   People's Republic of China   1,238 (426/812)   45                                      Surgery                     \<60 years, n=666; ≥60 years, n=572      2.3       DFS/OS    I/II/III      NSCLC        R(U)     7
  Go et al[@b27-ott-8-2731]          2014   Korea                        114 (87/27)       NR                                      Chemotherapy                NLR\<3.68 (44--80); NLR ≥3.69 (35--84)   3         OS        I/II/III/IV   NSCLC/SCLC   R(M)     5
  Kang et al[@b28-ott-8-2731]        2014   Korea                        187 (162/65)      40.28 (2.60--89.26)                     Surgery                     68 (43--84)                              4         PFS/OS    NR            SCLC         R(M)     6
  Kacan et al[@b29-ott-8-2731]       2014   Turkey                       299 (270/29)      13 (1--24)                              NR                          61 (31--82)                              5         OS        I/II/III/IV   NSCLC        R(M)     6
  Lin et al[@b30-ott-8-2731]         2014   People's Republic of China   81 (47/34)        12--51                                  TKI treatment               \<65 years, n=46; ≥65 years, n=35        3.5       PFS/OS    NR            NSCLC/SCLC   R(U/M)   7
  Pinato et al[@b16-ott-8-2731]      2014   UK                           220 (110/110)     13 (1--87)                              Surgery                     65                                       5         OS        I/II/III      NSCLC        R(U/M)   7
  Wang et al[@b31-ott-8-2731]        2014   People's Republic of China   114 (89/25)       NR                                      Surgery chemotherapy        \<70 years, n=92; ≥70 years, n=22        3         OS        NR            SCLC         R(M)     6
  Zhang et al[@b32-ott-8-2731]       2014   People's Republic of China   400 (272/128)     46 (1--78)                              Surgery                     60.8 (27--84)                            3.3       DFS/OS    I/II          NSCLC/SCLC   R(U/M)   7
  Botta et al[@b33-ott-8-2731]       2013   Italy                        112 (81/31)       15                                      Chemotherapy                62±11                                    4         PFS       III/IV        NSCLC        R(U)     6
  Forget et al[@b34-ott-8-2731]      2013   Belgium                      255               60                                      Surgery                     NR                                       5         PFS/OS    I/II          NSCLC        R(M)     5
  Yao et al[@b35-ott-8-2731]         2013   People's Republic of China   182 (119/63)      7.3 (1--30)                             Chemotherapy                61 (28--79)                              2.63      PFS/OS    III/IV        NSCLC        R(U/M)   7
  Yildirim et al[@b36-ott-8-2731]    2013   Turkey                       95 (77/18)        14±10.8                                 Chemotherapy                59 (30--88)                              5         OS        III/IV        NSCLC        E(M)     6
  Jafri et al[@b17-ott-8-2731]       2013   USA                          173               NR                                      Chemotherapy                57 (34--88)                              5         PFS/OS    NR            NSCLC        R(U)     5
  Kaya et al[@b37-ott-8-2731]        2013   Turkey                       156 (80/76)       17.6 (14.1--21.1)                       NR                          60 (30--88)                              5         OS        III/IV        NSCLC        E(M)     5
  Cedrés et al[@b38-ott-8-2731]      2012   Spain                        171 (143/28)      9.1 (1--70.37)                          Chemotherapy                63 (30--81)                              5         PFS/OS    IV            NSCLC        R(U/M)   7
  Lee et al[@b39-ott-8-2731]         2012   Korea                        199               36                                      Chemotherapy                57 (19--74)                              3.25      PFS/OS    III/IV        NSCLC        R(U/M)   6
  Sarraf et al[@b40-ott-8-2731]      2009   UK                           177 (104/73)      29 (8--56)                              Surgery                     63±10                                    3.8       OS        I/II/III/IV   NSCLC        R(U/M)   7
  Teramukai et al[@b41-ott-8-2731]   2009   Japan                        388 (276/122)     18.9 (2.3--57)                          Chemotherapy                65 (33--81)                              4.744     PFS/OS    III/IV        NSCLC        R(M)     6

**Abbreviations:** M, male; F, female; HR, hazard ratio; NOS, Newcastle--Ottawa Scale; OS, overall survival; NSCLC, non-small-cell lung cancer; E, estimating; R, reporting; M, multivariate; NR, not reported; NLR, neutrophil to lymphocyte ratio; PFS, progression-free survival; U, univariate analysis; RFS, recurrence-free survival; DFS, disease-free survival; TKI, tyrosine kinase inhibitor.

###### 

Summary of the meta-analysis results

  Analysis                          N    References                                                                                                                                                             Random-effects model   Fixed-effects model   Heterogeneity                          
  --------------------------------- ---- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- --------------------- ---------------------- ------- ------- -------
  Overall survival (OS)             21   [@b16-ott-8-2731],[@b17-ott-8-2731],[@b22-ott-8-2731]--[@b32-ott-8-2731],[@b34-ott-8-2731]--[@b41-ott-8-2731]                                                          1.506 (1.330, 1.706)   0                     1.229 (1.182, 1.276)   0       81.8    0
  Subgroup 1                                                                                                                                                                                                                                                                                        
   Surgery                          7    [@b16-ott-8-2731],[@b23-ott-8-2731],[@b26-ott-8-2731],[@b28-ott-8-2731],[@b32-ott-8-2731],[@b34-ott-8-2731],[@b40-ott-8-2731]                                          1.587 (1.264, 1.992)   0                     1.245 (1.182, 1.311)   0       87.7    0
   Chemotherapy                     7    [@b17-ott-8-2731],[@b27-ott-8-2731],[@b33-ott-8-2731],[@b35-ott-8-2731],[@b36-ott-8-2731],[@b38-ott-8-2731],[@b41-ott-8-2731]                                          1.305 (0.983, 1.733)   0                     1.148 (1.080, 1.221)   0       82.5    0.066
  Subgroup 2                                                                                                                                                                                                                                                                                        
   Eastern countries                13   [@b24-ott-8-2731],[@b26-ott-8-2731]--[@b32-ott-8-2731],[@b35-ott-8-2731]--[@b37-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                        1.638 (1.390, 1.931)   0                     1.302 (1.236, 1.370)   0       77.5    0
   Western countries                8    [@b16-ott-8-2731],[@b17-ott-8-2731],[@b22-ott-8-2731],[@b23-ott-8-2731],[@b25-ott-8-2731],[@b34-ott-8-2731],[@b38-ott-8-2731],[@b40-ott-8-2731]                        1.380 (1.067, 1.784)   0.014                 1.143 (1.079, 1.210)   0       84.6    0
  Subgroup 3                                                                                                                                                                                                                                                                                        
   Cut-off value =5                 9    [@b16-ott-8-2731],[@b17-ott-8-2731],[@b23-ott-8-2731],[@b25-ott-8-2731],[@b29-ott-8-2731],[@b34-ott-8-2731],[@b36-ott-8-2731]--[@b38-ott-8-2731]                       1.570 (1.164, 2.116)   0.003                 1.434 (1.270, 1.618)   0       81.70   0.405
   Cut-off value \<5                12   [@b22-ott-8-2731],[@b24-ott-8-2731],[@b26-ott-8-2731]--[@b28-ott-8-2731],[@b30-ott-8-2731]--[@b32-ott-8-2731],[@b35-ott-8-2731],[@b39-ott-8-2731]--[@b41-ott-8-2731]   1.472 (1.280, 1.693)   0                     1.208 (1.160, 1.257)   0       81.4    0
  Subgroup 4                                                                                                                                                                                                                                                                                        
   NSCLC                            16   [@b16-ott-8-2731],[@b17-ott-8-2731],[@b22-ott-8-2731]--[@b26-ott-8-2731],[@b29-ott-8-2731],[@b34-ott-8-2731]--[@b41-ott-8-2731]                                        1.447 (1.266, 1.654)   0                     1.215 (1.169, 1.263)   0       84.1    0
   SCLC                             2    [@b28-ott-8-2731],[@b31-ott-8-2731]                                                                                                                                    1.549 (1.156, 2.077)   0.003                 1.549 (1.156, 2.077)   0.003   0.00    0.626
   NSCLC/SCLC                       3    [@b27-ott-8-2731],[@b30-ott-8-2731],[@b32-ott-8-2731]                                                                                                                  2.073 (1.329, 3.234)   0.001                 2.070 (1.480, 2.895)   0       38      0.199
  Subgroup 5                                                                                                                                                                                                                                                                                        
   I/II/III/IV                      5    [@b24-ott-8-2731],[@b25-ott-8-2731],[@b27-ott-8-2731],[@b29-ott-8-2731],[@b40-ott-8-2731]                                                                              1.295 (1.073, 1.563)   0.007                 1.131 (1.065, 1.202)   0       50.3    0.090
   Advanced: III/IV                 6    [@b33-ott-8-2731],[@b35-ott-8-2731]--[@b37-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                                                             1.583 (1.222, 2.051)   0.001                 1.193 (1.121, 1.269)   0.001   77.7    0
  Subgroup 6                                                                                                                                                                                                                                                                                        
   Sample size ≥200                 8    [@b16-ott-8-2731],[@b23-ott-8-2731],[@b25-ott-8-2731],[@b26-ott-8-2731],[@b29-ott-8-2731],[@b32-ott-8-2731],[@b34-ott-8-2731],[@b41-ott-8-2731]                        1.576 (1.433, 1.733)   0                     1.565 (1.441, 1.699)   0       5.9     0.385
   Sample size \<200                13   [@b17-ott-8-2731],[@b22-ott-8-2731],[@b24-ott-8-2731],[@b27-ott-8-2731],[@b28-ott-8-2731],[@b30-ott-8-2731],[@b31-ott-8-2731],[@b35-ott-8-2731]--[@b40-ott-8-2731]     1.395 (1.202, 1.619)   0                     1.149 (1.101, 1.200)   0       79.9    0
  Subgroup 7                                                                                                                                                                                                                                                                                        
   Univariate analysis              13   [@b16-ott-8-2731],[@b17-ott-8-2731],[@b22-ott-8-2731]--[@b26-ott-8-2731],[@b30-ott-8-2731],[@b32-ott-8-2731],[@b35-ott-8-2731],[@b38-ott-8-2731]--[@b40-ott-8-2731]    1.420 (1.242, 1.623)   0                     1.200 (1.160, 1.241)   0       88.2    0.001
   Multivariate analysis            17   [@b16-ott-8-2731],[@b23-ott-8-2731],[@b24-ott-8-2731],[@b27-ott-8-2731]--[@b32-ott-8-2731],[@b34-ott-8-2731]--[@b41-ott-8-2731]                                        1.581 (1.386, 1.803)   0                     1.189 (1.139, 1.240)   0       74.9    0
  Progression-free survival (PFS)   9    [@b17-ott-8-2731],[@b28-ott-8-2731],[@b30-ott-8-2731],[@b33-ott-8-2731]--[@b35-ott-8-2731],[@b38-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                       1.334 (1.066, 1.670)   0.012                 1.230 (1.161, 1.304)   0       80.5    0
  Subgroup 1                                                                                                                                                                                                                                                                                        
   Surgery                          2    [@b28-ott-8-2731],[@b34-ott-8-2731]                                                                                                                                    1.462 (1.138, 1.877)   0.003                 1.462 (1.138, 1.877)   0.003   0.00    0.949
   Chemotherapy                     6    [@b17-ott-8-2731],[@b33-ott-8-2731],[@b35-ott-8-2731],[@b38-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                                            1.173 (0.901, 1.527)   0.235                 1.207 (1.137, 1.282)   0       82.0    0
  Subgroup 2                                                                                                                                                                                                                                                                                        
   Eastern countries                5    [@b28-ott-8-2731],[@b30-ott-8-2731],[@b35-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                                                              1.598 (1.216, 2.099)   0.001                 1.266 (1.190, 1.347)   0       73.3    0.005
   Western countries                4    [@b17-ott-8-2731],[@b33-ott-8-2731],[@b34-ott-8-2731],[@b38-ott-8-2731]                                                                                                1.065 (0.683, 1.660)   0.782                 0.991 (0.836, 1.175)   0.919   84.30   0
  Subgroup 3                                                                                                                                                                                                                                                                                        
   Cut-off value =5                 3    [@b17-ott-8-2731],[@b34-ott-8-2731],[@b38-ott-8-2731]                                                                                                                  0.941 (0.575, 1.541)   0.809                 0.930 (0.776, 1.113)   0.429   86.30   0.001
   Cut-off value \<5                6    [@b28-ott-8-2731],[@b30-ott-8-2731],[@b33-ott-8-2731],[@b35-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                                            1.596 (1.250, 2.037)   0                     1.271 (1.195, 1.351)   0       68.9    0.007
  Subgroup 4                                                                                                                                                                                                                                                                                        
   Univariate analysis              6    [@b17-ott-8-2731],[@b30-ott-8-2731],[@b33-ott-8-2731],[@b35-ott-8-2731],[@b38-ott-8-2731],[@b39-ott-8-2731]                                                            1.361 (0.956, 1.938)   0.087                 1.227 (1.159, 1.299)   0       88.5    0
   Multivariate analysis            6    [@b28-ott-8-2731],[@b30-ott-8-2731],[@b34-ott-8-2731],[@b35-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                                            1.547 (1.237, 1.935)   0                     1.271 (1.196, 1.351)   0       67.9    0.008
   NSCLC                            7    [@b17-ott-8-2731],[@b33-ott-8-2731]--[@b35-ott-8-2731],[@b38-ott-8-2731],[@b39-ott-8-2731],[@b41-ott-8-2731]                                                           1.205 (0.958, 1.517)   0.112                 1.213 (1.143, 1.287)   0       79.2    0

**Note:** Meta-regression analysis was applied only if the pooled cohorts exceeded 10.

**Abbreviations:** N, number of studies; HR, hazard ratio; CI, confidence interval, *Ph*, *P*-value of *Q*-test for heterogeneity test; NSCLC, non-small-cell lung cancer.
